---
title: "Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies"
description: "Company advanced efforts to secure U.S. FDA 510 ( k ) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings ..."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253235315.md"
published_at: "2025-08-15T13:32:14.000Z"
---

# Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

> Company advanced efforts to secure U.S. FDA 510 ( k ) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings ...

Company advanced efforts to secure U.S. FDA 510 ( k ) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings ...

### Related Stocks

- [INBS.US - Intelligent Bio Solutions](https://longbridge.com/en/quote/INBS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Intelligent Bio Solutions Regains Nasdaq Compliance After Bid Price Recovery | Intelligent Bio Solutions Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock maint | [Link](https://longbridge.com/en/news/271989471.md) |
| Intelligent Bio Solutions Signs Multiple Financing Agreements | Intelligent Bio Solutions has signed multiple financing agreements to complete a $10 million private placement of common | [Link](https://longbridge.com/en/news/271365754.md) |
| A Goldman Sachs partner in technology shares the skills young job seekers need in the AI workplace | A Goldman Sachs partner in technology shares the skills young job seekers need in the AI workplace | [Link](https://longbridge.com/en/news/275976341.md) |
| CICC Reaffirms Their Buy Rating on NIO Inc. Class A (9866) | CICC analyst maintained a Buy rating on NIO Inc. Class A yesterday and set a price target of HK$50.00.Valentine's Day Sa | [Link](https://longbridge.com/en/news/275967598.md) |
| Execution Risks Mount as Crocs Bets Heavily on HEYDUDE Integration and Concentrated Manufacturing Base | Crocs (CROX) faces heightened execution risks as it integrates HEYDUDE, acquired in 2022. The company's future growth de | [Link](https://longbridge.com/en/news/275971905.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.